Artificial intelligence is increasingly embedded in biopharma, with innovative AI platforms transforming drug discovery and precision medicine. Stanford Medicine unveiled CRISPR-GPT, an AI assistant that streamlines genome editing experiment design. Separately, Parse Biosciences launched the Evercode™ WT Penta platform enabling massive-scale single-cell transcriptomic analysis, critical for oncology research. Flexynesis, a deep learning toolkit, integrates bulk multi-omics data for improved cancer diagnosis and treatment stratification. These technologies exemplify how machine learning is revolutionizing biomedical research and therapeutic development.